

PATENT SPECIFICATION

(11) 1 585 963

1 585 963

- (21) Application No. 42683/76 (22) Filed 14 Oct. 1976
 (23) Complete Specification filed 14 Oct. 1977
 (44) Complete Specification published 11 March 1981
 (51) INT CL³ C07C 147/14 A61K 31/10 C07C 149/36
 (52) Index at acceptance

C2C 220 227 22Y 30Y 313 31Y 338 365 36Y 373 37Y 397 613 623
 662 699 775 801 802 80Y AA QN

- (72) Inventors DELME EVANS
 JOHN CHRISTOPHER SAUNDERS and
 WILLIAM ROBERT NIGEL WILLIAMSON




(54) ARYL SULPHUR COMPOUNDS

(72) We, LILLY INDUSTRIES LIMITED, a British company of Lilly House, Hanover Square, London W1R 0PA formerly of Henrietta House, Henrietta Place, London, W.1, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

This invention relates to a class of novel aryl sulphur compounds, to methods of preparing such compounds, to pharmaceutical formulations and to methods of treating allergic conditions involving use of such compounds.

According to the present invention there is provided an aryl sulphur compound of formula (I):



wherein R¹ is C₁₋₄ alkyl, Ar is a phenyl group optionally substituted by halogen or C₁₋₄ alkyl and wherein Z is S or SO₂, or a pharmaceutically acceptable salt thereof.


25 Preferably R¹ is ethyl and/or Ar represents a phenyl group substituted with a *para*-substituent such as chlorine or methyl.

The invention also provides a pharmaceutical formulation which comprises a compound of formula (I), or a pharmaceutically-acceptable salt thereof, associated with a pharmaceutically acceptable carrier therefor.

35 The invention further provides a method of treating a mammal susceptible to an allergic condition, and particularly a method of treating immediate hypersensitivity diseases such as asthma, which comprises administering to the animal a therapeutically effective amount of a compound of formula (I) as defined above.

40 In a further aspect of the invention there

is provided a method of making a compound of formula (I) as defined above, which method comprises reacting together a compound of formula:



and a compound of formula:

ArSH

in the presence of chlorine to give a compound of formula (I) in which Z is S; followed if desired, by oxidation to give a compound of formula (I) in which Z is SO₂.

Oxidation of a compound of formula (I) in which Z is S may advantageously be effected using hydrogen peroxide. Substantially equimolar quantities of the compound of formula (I) and hydrogen peroxide should be used.

Use of hydrogen peroxide in excess of two moles per mole of the compound of formula (I) in which Z is S should be avoided since this will lead to the formation of a compound of the type (I) in which Z is SO₂.

The aryl sulphur compounds of the present invention are useful in the prophylactic treatment of immediate hypersensitivity diseases including asthma and in the alleviation of *status asthmaticus* in humans. The compounds have low toxicity.

The compounds of compositions of the present invention may be administered by various routes and for this purpose may be formulated in a variety of forms. Thus the compounds or compositions may be administered by the oral and rectal routes, topically, parenterally, e.g. by injection and by continuous or discontinuous intra-arterial infusion, in the form of, for example, tablets, lozenges, sub-lingual tablets, sachets, cachets, elixirs, suspensions,

aerosols, ointment, for example, containing from 1 to 10% by weight of the active compound in a suitable base, soft and hard gelatin capsules, suppositories, injection solutions and suspensions in physiologically acceptable media, and sterile packaged powders absorbed onto a support material for making injection solutions. Advantageously for this purpose, compositions may be provided in dosage unit form preferably each dosage unit containing from 5 to 500 mg. (from 5.0 to 50 mg. in the case of parenteral administration, from 5.0 to 50 mg. in the case of inhalation and from 25 to 500 mg. in the case of oral or rectal administration) of a compound of formula (I).

Dosages of from 0.5 to 100 mg/kg per day, preferably 2 to 20 mg/kg, of active ingredients may be administered. It will however readily be understood that the amount of the compound or compounds of formula (I) actually to be administered will be determined by a physician, in the light of all the relevant circumstances including the condition to be treated, the choice of compound to be administered and the choice of route of administration and therefore the above preferred dosage range is not intended to limit the scope of the present invention in any way. The invention will be further illustrated by the following Examples:

EXAMPLE 1

4-Ethyl-2-(phenylthio)phenol
Chlorine gas was passed into a stirred cooled (0°C) solution of 4-ethylphenol (30.5g) and thiophenol (22g) in dichloromethane (100ml) for 3 hours. The solution was stirred overnight at room temperature the solvent was distilled off on a rotary evaporator and the residual oil was distilled, the product being in the higher boiling fraction (160—180°C at about 0.5 cm Hg). This fraction was chromatographed on a silica column, being eluted with hexane progressively enriched with chloroform to give the title compound (12.5g), as a clear liquid, $n_D^{25}=1.6130$.

EXAMPLES 2 AND 3

There was also prepared by the method of Example 1 the following:
2-(4-Chlorophenylthio)-4-ethylphenol, $n_D^{25}=1.6205$; and
4-Ethyl-2-(4-methylphenylthio)phenol.

EXAMPLE 4

2-(4-Chlorophenylsulphinyl)-4-ethylphenol
2-(4-Chlorophenylthio)-4-ethylphenol (1.3g) was dissolved in glacial acetic acid (50 ml) and treated with aqueous hydrogen peroxide (0.57 ml 30% W/V). The mixture was kept under nitrogen and heated under

reflux for one hour. On cooling, the solution was poured into water (400 ml) and a gummy solid separated out. This gummy solid was extracted with ethyl acetate and the organic fraction was washed with water, dried over magnesium sulphate and evaporated leaving a residual oil. The oil was dissolved in hot hexane, charcoaled, filtered and cooled, whereupon the title compound separated as a white crystalline solid (0.7g) (mp 137°C).

EXAMPLES 5 AND 6


There were prepared by the method of Example 4, the following:

4-Ethyl-2-(phenylsulphinyl)phenol, m.p. 145°C, and


4-Ethyl-2-(4-methylphenylsulphinyl)phenol.

WHAT WE CLAIM IS:—

1. A method of preparing an aryl sulphur compound of formula (I):



wherein R^1 is C_{1-4} alkyl; Ar is a phenyl group optionally substituted by halogen or C_{1-4} alkyl and wherein Z is S or SO, which method comprises reacting a compound of formula:




and a compound of the formula



in the presence of chlorine to give a compound of formula (I) in which Z is S; followed, if desired, by oxidation to give a compound of formula (I) in which Z is SO.

2. A method according to claim 1 wherein R^1 is ethyl.

3. An aryl sulphur compound of formula (I):



wherein R^1 is C_{1-4} alkyl; Ar is a phenyl

group optionally substituted by halogen or C₁₋₄ alkyl and where Z is S or SO, or a pharmaceutically-acceptable salt thereof.

5 4. A compound of formula (I) as claimed in claim 3 wherein R¹ is ethyl.

10 5. A pharmaceutical formulation comprising a compound of formula (I) as claimed in claim 3, or a pharmaceutically-acceptable salt thereof, associated with a pharmaceutically acceptable carrier therefor.

15 6. A method of treating a non-human mammal susceptible to an immediate hypersensitivity condition which comprises administering a therapeutically effective

amount of compound of formula (I) to the mammal.

7. A compound of formula (I) as claimed in Claim 3 substantially as hereinbefore described with reference to any one of the Examples. 20

8. A method according to Claim 1 substantially as hereinbefore described with reference to any one of the Examples.

K. W. H. McVEY,
Chartered Patent Agent
Erl Wood Manor,
Windlesham,
Surrey, England.
Agent for the Applicants.